ClinicalTrials.Veeva

Menu

A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Breast Neoplasms

Treatments

Drug: SU011248

Study type

Interventional

Funder types

Industry

Identifiers

NCT00078000
A6181002

Details and patient eligibility

About

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.

Enrollment

64 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Anthracycline and taxane-refractory or intolerant metastatic breast cancer
  • Female

Exclusion criteria

  • Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems